Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AR-301 plus standard-of-care antibiotics for Staphylococcus aureus ventilator-associated pneumonia
CTR20191544Phase 3Active
- Sponsor
- Shenzhen Arimab Biopharmaceuticals
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tosatoxumab in Staphylococcus aureus ventilator-associated pneumonia (SA-VAP), sponsored by Shenzhen Arimab Biopharmaceuticals. Started Jun 2021; status: active.
02
Drugs
tosatoxumab
03
Conditions
Staphylococcus aureus ventilator-associated pneumonia (SA-VAP)
Beyond the preview
Go deeper on CTR20191544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191544.